×
AngioDynamics shares fell roughly 26.8% over the last 30 days, from $15.22 on September 8 to about $11.14, with most of the decline arriving after the company's fiscal first-quarter report. The company beat fiscal Q1 2027 revenue and adjusted EPS estimates yet still posted a GAAP loss, and the stock dropped more than 20% in the session following the results.
ANGO is down -21.49% to $11.14 during regular market hours, extending pre-market weakness that had already pushed shares roughly -8% lower. The drop follows fiscal Q1 2027 results: adjusted EPS of -$0.04 beat the -$0.11 consensus and revenue of $80.9M topped the $80.5M estimate, yet shares sold off.
The central $20 price target is the arithmetic mean of four verified analyst targets, which span a wide range from $17 to $24. At a recent close near $14.19, reaching $20 would require a gain of roughly 41%, a substantial move.
Med Tech set to become the majority of revenue in fiscal 2027 , up from 47% in fiscal 2026, signaling a durable mix shift toward faster-growing platforms. Three growth engines anchor the strategy : Auryon (peripheral atherectomy), mechanical thrombectomy (AngioVac and AlphaVac), and the NanoKnife oncology platform.
AtriCure (ATRC) shares climbed roughly 26% over the last 30 days, rising from about $48.17 to a closing level near $60.77. The rally has been part of a broader multi-month advance, with the stock trading at or near 52-week highs through mid-to-late September 2026.
PLSE is trading down -6.3% (about -$3.48) during regular market hours, near $51.72 versus a prior close of $55.20. The primary catalyst is a newly announced $85 million at-the-market equity distribution agreement with Mizuho, raising shareholder dilution concerns.
COO is down -15.5% to roughly $53.64, extending a -6.2% drop in Wednesday's regular session after reporting fiscal Q3 results after the close. The primary catalyst was a Q3 revenue miss ($1.066B vs. ~$1.098B consensus) driven by CooperVision's U.S. channel inventory destocking.
MMED closed at $23.29 on September 4, down -2.31% (-$0.55) from the prior session's $23.84 close during regular trading hours. The primary catalyst was the completed ~$805 million public offering of common stock, which triggered investor concerns over share dilution and a sharply larger share count.
Medline shares have been roughly flat over the trailing 30 days, holding near the $36–37 range after a volatile summer that saw the stock slide from its early-August highs. Second-quarter 2026 revenue rose 11.6% year over year to $7.7 billion, while net income fell 58.3% amid tariff headwinds and higher operating costs.
Selected target: $500 per share, a round-number milestone that sits roughly one-third above recent prices near $375. Bullish case: The da Vinci 5 upgrade cycle, strong international procedure growth, and a consensus analyst rating of Buy support the upside narrative.
MMED shares climbed roughly 15.4% over the last 30 days, from a closing price of $16.93 on July 17, 2026, to $19.53 at the latest available close. The advance was supported by expanded U.S. Medicare access to the MiniMed Flex system, the start of commercial U.S. shipments with Abbott's Instinct sensor, and favorable analyst actions.
NNNN rallied +39.10% to $12.38 in early regular trading Monday, extending a premarket gain of roughly +18%. The advance occurred during normal market hours, with NNNN opening near $12.00 and touching a $12.64 session high.
Selected target: $20 per share, roughly 44% above Avantor's recent price near $13.93 and above the highest current Street target of $19. Strongest bullish factors: a second-quarter earnings beat, raised fiscal 2026 adjusted EPS guidance, cost-savings turnaround efforts, a $500 million buyback authorization, and expansion in high-purity silicone applications.
Revenue: Net sales reached $2.78 billion, up 8% year-over-year and modestly ahead of the $2.77 billion consensus estimate. Core EPS: Core diluted earnings per share (EPS) came in at $0.84, beating analyst expectations of approximately $0.76–$0.77 by roughly 9–11%.
Price Target: $25 represents a roughly 27.5% upside from the current price near $19.60 and sits at the top of Wall Street's 12-month analyst target range. Bull Case: Multiple prominent firms — including BTIG, UBS, and Wells Fargo — have assigned price targets at or above $25, citing double-digit revenue growth, expanding margins, and a rapidly growing $18 billion global diabetes technology market.
Alcon (ALC) is scheduled to report second-quarter 2026 earnings on Monday, August 10, after the market close, followed by a conference call on Tuesday morning. Wall Street consensus projects core earnings per share (EPS) of approximately $0.75 to $0.77 on revenue of roughly $2.77 billion , implying modest year-over-year EPS growth and a roughly 7% revenue increase.
LMAT plunged -24.28% during Wednesday's regular session, extending an after-hours selloff that began Tuesday evening following the company's Q2 2026 earnings release after the close. Q2 2026 results missed consensus: adjusted EPS of $0.74 versus the $0.81 estimate, and revenue of $70.38M versus the $71.47M forecast, despite 10% organic sales growth year-over-year.
MDLN shares fell -11.67% during regular trading on Wednesday after the company reported Q2 2026 earnings that revealed a 58.3% year-over-year drop in net income to $139 million. The steep profit decline was driven by $336 million in losses from a fire that destroyed its 1-million-square-foot distribution center in Tracy, California, before expected insurance recoveries.
Intuitive Surgical shares dropped approximately 15% over the past 30 days, accelerating sharply after the company's second-quarter 2026 earnings report released on July 16. Q2 revenue rose 19% year-over-year to $2.89 billion and adjusted EPS of $2.80 beat Wall Street estimates, yet investors focused on unchanged full-year procedure growth guidance.
STAA shares fell -11.42% during Monday's regular session to $23.42, extending Friday's -8.76% rout for a combined two-day decline of roughly -19%. The sell-off originated from Thursday's preliminary Q2 revenue announcement, which beat estimates at $90M+ but lacked any second-half 2026 guidance, sparking analyst caution.